Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells

Sherman, 1995, Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis, J. Cell. Biochem., Suppl., 23, 160, 10.1002/jcb.240590921 Bokhman, 1983, Two pathogenetic types of endometrial carcinoma, Gynecol. Oncol., 15, 10, 10.1016/0090-8258(83)90111-7 Dunlop, 1997, Cancer risk associated with germline DNA mismatch repair gene mutations, Hum. Mol. Genet., 6, 105, 10.1093/hmg/6.1.105 Ryan, 2005, Endometrial cancer, Cell Tissue Res., 322, 53, 10.1007/s00441-005-1109-5 Lax, 2000, The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways, Cancer, 88, 814, 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U Enomoto, 1991, K-ras activation in premalignant and malignant epithelial lesions of the human uterus, Cancer Res., 51, 5308 Risinger, 1997, PTEN/MMAC1 mutations in endometrial cancers, Cancer Res., 57, 4736 Mutter, 2000, Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers [see comments], J. Natl. Cancer Inst., 92, 924, 10.1093/jnci/92.11.924 Leslie, 2005, Progesterone receptor isoform identification and subcellular localization in endometrial cancer, Gynecol. Oncol., 96, 32, 10.1016/j.ygyno.2004.09.057 Moll, 1996, Uterine papillary serous carcinoma evolves via a p53-driven pathway, Hum. Pathol., 27, 1295, 10.1016/S0046-8177(96)90340-8 Zheng, 1996, p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes, Gynecol. Oncol., 61, 167, 10.1006/gyno.1996.0120 Kounelis, 2000, Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature, Mod. Pathol., 13, 379, 10.1038/modpathol.3880062 Steck, 1997, Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers, Nat. Genet., 15, 356, 10.1038/ng0497-356 Yin, 1999, Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress, Mol. Carcinog., 24, 15, 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.0.CO;2-Y Semczuk, 2004, Clinicoprognostic significance of pRb1 pathway alterations in uterine endometrial adenocarcinoma, Cancer Genet. Cytogenet., 154, 186, 10.1016/j.cancergencyto.2004.05.016 Armes, 2005, Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein, Int. J. Gynecol. Pathol., 24, 363, 10.1097/01.pgp.0000172083.94934.1e Classon, 2001, p107 and p130: versatile proteins with interesting pockets, Exp. Cell Res., 264, 135, 10.1006/excr.2000.5135 Nishida, 2002, The Ishikawa cells from birth to the present, Hum. Cell, 15, 104, 10.1111/j.1749-0774.2002.tb00105.x Davies, 2004, Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells, J. Soc. Gynecol. Investig., 11, 494, 10.1016/j.jsgi.2004.04.003 Leslie, 1997, Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation, Ann. N. Y. Acad. Sci., 828, 17, 10.1111/j.1749-6632.1997.tb48520.x Kumar, 1998, Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action, Cancer Res., 58, 1860 Dai, 2005, A therapeutic model for advanced endometrial cancer: Systemic progestin in combination with local adenoviral-mediated progesterone receptor expression, Mol. Cancer Ther., 4, 169, 10.1158/1535-7163.169.4.1 Shaffer, 2005 Wan, 2002, PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway, Cell Death Differ., 9, 414, 10.1038/sj.cdd.4400982 Weng, 2001, PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model, Hum. Mol. Genet., 10, 599, 10.1093/hmg/10.6.599 Pajalunga, 2004, Regulation of cyclin E protein levels through E2F-mediated inhibition of degradation, Cell Cycle, 3, 1572, 10.4161/cc.3.12.1279 T'Ang, 1989, Genomic organization of the human retinoblastoma gene, Oncogene, 4, 401 Lee, 1988, Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79, Proc. Natl. Acad. Sci. U. S. A., 85, 6017, 10.1073/pnas.85.16.6017 Slingerland, 1991, Mutation of the p53 gene in human acute myelogenous leukemia, Blood, 77, 1500, 10.1182/blood.V77.7.1500.1500 Yaginuma, 1996, Analysis of the retinoblastoma gene in human endometrial carcinoma, Obstet. Gynecol., 87, 755, 10.1016/0029-7844(96)00010-5 Ellenson, 2004, Focus on endometrial and cervical cancer, Cancer Cell, 5, 533, 10.1016/j.ccr.2004.05.029